Nur auf Docsity: Lade Chronic Kidney Disease und mehr Übungen als PDF für Corporate Finance herunter!
Chronic
Kidney
Disease
Chronic Kidney Disease (CKD) is defined as abnormalities of kidney structure or function, present for more than three months, with significant implications for health. To prepare this comprehensive, exam- ready resource, the most current 2025/2026 evidence and KDIGO guidelines have been integrated to provide a structured framework for the evaluation, advanced hormonal assessment, and management of this condition.
📘 Part 1 : Core Concepts – Definition, Staging, and Pathophysiology
The diagnosis of CKD is not made with a single isolated abnormal measurement. It requires persistence of damage for at least three months. The kidney's integral role in hormone production means that endocrine abnormalities are virtually universal as the disease progresses.
1.1 The KDIGO 2024/2025 Definition and Staging Matrix
The definitive diagnosis and staging of CKD is based on a three-pronged system:
- Cause: Identifying the underlying etiology.
- GFR category: Based on estimated glomerular filtration rate (eGFR).
- Albuminuria category: Based on the urine albumin-to-creatinine ratio (uACR). Staging in KDIGO is based on both eGFR and albuminuria, with the uACR now emphasized alongside eGFR in both diagnosis and monitoring. More frequent monitoring (every 3-4 months) is recommended for patients with higher risk categories (e.g., G2A3) given the severely elevated albuminuria. | GFR Category | eGFR | Term | Albuminuria Category | uACR (mg/g) | Term | | :--- | :--- | :--- | :--- | :--- | :--- | | G1 | ≥90 | Normal or high | A1 | <30 | Normal to mildly increased | | G2 | 60–89 | Mildly decreased | A2 | 30–300 | Moderately increased | | G3a | 45–59 | Mildly to moderately decreased | A3 | >300 | Severely increased | | G3b | 30–44 | Moderately to severely decreased | | | | | G4 | 15–29 | Severely decreased | | | | | G5 | <15 | Kidney failure | | | |
1.2 Pathophysiology – A Self‑Perpetuating Cycle
The pathophysiological process of CKD initiates a vicious cycle:
- Initial Injury: Diabetes or hypertension are the most common causes, leading to nephron loss.
- Hyperfiltration: Remaining healthy nephrons increase their workload to compensate, leading to further damage.
- RAAS Activation: Reduced renal perfusion activates the renin-angiotensin-aldosterone system (RAAS). While initially compensatory, chronic RAAS activation causes further glomerular hypertension and fibrosis.
- Hormonal Dysfunction: As functional nephrons are lost, the kidneys fail to produce active vitamin D and erythropoietin (EPO), and cannot excrete phosphorus or acid, leading to systemic hormonal disturbances (SHPT, anemia, metabolic acidosis).
| | Serum Urea, Cystatin C (if available) | Helps confirm eGFR accuracy; improves risk prediction when combined with creatinine. | | Minerals and Bones | Calcium, Phosphate, PTH, 25(OH)Vitamin D | Essential for diagnosing and monitoring CKD-MBD. | | Anemia Panel | Complete Blood Count (CBC), Reticulocyte count, Ferritin, Transferrin saturation (TSAT) | Detects anemia, a common complication beginning in early CKD stages. | | Acid‑Base & Electrolytes | Bicarbonate (CO2), Sodium, Potassium, Chloride | Identifies metabolic acidosis and dangerous electrolyte imbalances. | | Nutritional | Albumin, Pre‑albumin, Lipid panel | Assesses nutritional status and cardiovascular risk. | | Urinalysis | Dipstick (blood, protein), Microscopy for RBC casts, dysmorphic RBCs, WBCs, crystals | Key for identifying glomerulonephritis. RBC casts indicate glomerular bleeding. | | Imaging | Renal Ultrasound | Essential to assess kidney size and echotexture. Small, echogenic kidneys suggest irreversible CKD. Normal or large kidneys suggest acute disease, infiltrative disease
(amyloid), or Polycystic Kidney Disease (PCKD). |
🔬 Part 3 : Advanced Hormonal Evaluation – The Endocrine Web of CKD
Hormonal disorders are common complications of chronic kidney disease. The kidneys are central to the metabolism and production of several key hormones, making endocrine abnormalities a hallmark of advancing CKD.
3.1 Renin-Angiotensin-Aldosterone System (RAAS)
The intrarenal RAAS may be activated even when circulating RAAS levels are suppressed. This activation is central to the pathophysiology of CKD progression, driving renal fibrosis and glomerular hypertension.
3.2 Mineral Metabolism: The CKD-MBD Axis
Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is a systemic condition, defined by laboratory abnormalities involving calcium, phosphorus, PTH, and FGF-23, as well as bone abnormalities and soft tissue calcification.
Hormone/BiomarkerChanges in CKDPhysiologyClinical Action PhosphateRises in late CKD stages (G4-G5)The failing kidney cannot excrete dietary phosphorus.Dietary restriction, phosphate binders.
Fibroblast Growth Factor 23 (FGF-23)Increases very early in CKD (G2-G3)Maintains normal serum phosphate by increasing renal excretion.Currently a research tool, not yet used clinically.
Calcitriol (1,25-Dihydroxyvitamin D)Decreases early in CKDDue to reduced kidney 1- alpha-hydroxylase activity.Supplementation with calcitriol or analogs.
Parathyroid Hormone (PTH)Rises in stage 3 and beyondLow calcium and low vitamin D stimulate PTH release.
First-line therapy is vitamin D repletion. Soluble α-KlothoDecreases early in CKDA co-receptor for FGF-23.Research use only.
Clinical Management of SHPT: The KDIGO guidelines recommend monitoring calcium, phosphate, and PTH levels at regular intervals. Initial management includes controlling phosphatemia with dietary restriction and binders, followed by vitamin D repletion, and finally calcimimetics (e.g., cinacalcet) in refractory cases.
3.3 Anemia: An Endocrinopathy of EPO Deficiency
The anemia of CKD is multifactorial, but the primary driver is the kidney's reduced production of the hormone erythropoietin (EPO), which stimulates red blood cell production in the bone marrow.
- Inflammation: Chronic inflammation in CKD increases levels of hepcidin, a hormone that blocks iron absorption in the gut, creating a functional iron deficiency.
- Evaluation: The 2026 KDIGO Guideline recommends a thorough evaluation of anemia in CKD patients. This includes a CBC, reticulocyte count, and iron studies.
- Management:
- First-Line: Oral or intravenous iron, to replenish stores. Intravenous iron is often preferred due to the hepcidin block.
| Glycemic Control | Slows nephron loss (in diabetes) | Target HbA1c 7.0-8.0% (avoid <6.5% due to hypoglycemia risk). | | Dietary Modification | Reduces waste product accumulation | Low sodium (<2.3g/day), low protein (0.6-0.8 g/kg/day) in advanced stages. | | Metabolic Acidosis | Reduces progression and muscle catabolism | Treat with oral sodium bicarbonate to maintain serum bicarbonate >22 mmol/L. | | Potassium Management | Prevents life-threatening arrhythmia | Dietary potassium restriction;
use of potassium binders. |
🩺 Part 5 : Clinical Case Studies
Case Study 1: A 55‑Year‑Old Man with Diabetes – A Classic Presentation of Diabetic Kidney Disease
History: A 55-year-old man with a 15-year history of poorly controlled type 2 diabetes presents with frothy urine and progressive swelling in his legs for 3 months. He reports a recent HbA1c of 9.2%. He is on metformin and lisinopril. Work-up:
- Physical Exam: BP 145/92 mmHg, bilateral pitting edema.
- Labs: Serum creatinine 1.7 mg/dL (eGFR = 43 mL/min). Urinalysis shows 3+ protein and no RBCs. A spot uACR is >1200 mg/g.
- Diagnosis: Stage G3bA3 CKD, most likely diabetic kidney disease (DKD). Management:
- RAAS Blockade: The lisinopril dose is maximized as tolerated to reduce BP and proteinuria.
- SGLT2 Inhibitor: Start Empagliflozin 10 mg daily for nephroprotection.
- Glycemic Control: Add a GLP-1 agonist (e.g., semaglutide) for cardiovascular and renal benefits, reducing sulfonylurea.
- Patient Education: Focus on strict BP monitoring, daily weights to assess fluid status, and a low- sodium diet.
Outcome: After 6 months, his BP is 128/80 mmHg, his uACR has dropped to 800 mg/g, and his eGFR has stabilized.
Case Study 2: A 78‑Year‑Old Woman on Warfarin – An Acute Kidney Injury Unveils Underlying CKD
History: A 78-year-old woman with atrial fibrillation, heart failure, and a baseline creatinine of 1. mg/dL presents with nausea, vomiting, and a 3-day history of coffee-colored urine. Work-up:
- Labs: INR is supratherapeutic at 7.5, creatinine is 3.2 mg/dL (eGFR 18). Urinalysis reveals dysmorphic RBCs.
- Imaging: Renal ultrasound shows normal-sized, echogenic kidneys.
- Diagnosis: The dysmorphic RBCs point to glomerulonephritis. Given the history of anticoagulation, a kidney biopsy is performed, revealing "Crescentic IgA Nephropathy." Management:
- Withdraw Warfarin: Immediate reversal with Vitamin K and fresh frozen plasma.
- Immunosuppression: High-dose intravenous steroids followed by oral prednisone to halt the rapidly progressive glomerulonephritis.
- Blood Pressure Control: Aggressive BP management. Outcome: Her creatinine improved to 1.6 mg/dL after 3 months, but this episode of acute-on- chronic disease progressed her underlying CKD.
Case Study 3: The Hidden Hormonal Causes of Worsening Renal Function – Hypothyroidism
History: A 65-year-old woman with stable stage 3b CKD (eGFR of 45 mL/min) presents with severe fatigue, weakness, and weight gain. Over 2 months, her eGFR declines to 28 mL/min without an obvious cause. Work-up:
- Discuss Renal Replacement Therapy (RRT): Initiation of hemodialysis to help control uremia and phosphorus.
📝 Part 6 : Exam‑Style Questions & Answers
Multiple Choice Questions
Q1: A 55-year-old man with a 10-year history of type 2 diabetes presents for routine follow-up. Laboratory results show an eGFR of 55 mL/min and a urine albumin-to-creatinine ratio (uACR) of 180 mg/g. According to the KDIGO 2024 classification, what is this patient's CKD stage? A) G2A B) G3aA C) G3aA D) G2A > Answer: B > Explanation: This patient has an eGFR of 55 mL/min, which corresponds to G3a (45- 59 mL/min). The uACR is 180 mg/g, which falls into the A2 (30-300 mg/g) category for moderately increased albuminuria. The correct staging is therefore G3aA2. Q2: A 68-year-old woman with stage 4 CKD (eGFR 27) complains of severe, diffuse bone pain and generalized pruritus. Labs show a corrected calcium of 8.2 mg/dL (normal 8.5-10.2), phosphorus of 6. mg/dL, a PTH of 700 pg/mL, and a low 25-hydroxyvitamin D. What is the most appropriate initial step in management? A) Start a high-dose phosphate binder B) Start cinacalcet to directly lower PTH C) Replete with ergocalciferol or cholecalciferol D) Refer for parathyroidectomy
> Answer: C > Explanation: This patient has advanced secondary hyperparathyroidism (SHPT) driven largely by vitamin D deficiency. The KDIGO guidelines for managing SHPT emphasize that vitamin D deficiency should be corrected first. All subsequent steps (phosphate binders, cinacalcet) are less effective in the setting of low vitamin D. Q3: A 48-year-old man with stage 3a CKD (eGFR 48) has anemia with a hemoglobin of 10.2 g/dL. A complete workup reveals ferritin of 800 ng/mL and a transferrin saturation (TSAT) of 15%. What is the most likely underlying mechanism for the persistent anemia? A) Pure red cell aplasia B) Bone marrow suppression from chemotherapy C) Functional iron deficiency due to high hepcidin levels D) Folic acid deficiency > Answer: C > Explanation: This patient has high ferritin (adequate iron stores) but low TSAT (poorly available iron). This pattern is characteristic of functional iron deficiency, which in CKD is driven by high levels of the hormone hepcidin. Hepcidin traps iron in storage sites, preventing its use for erythropoiesis. Intravenous iron is often required to bypass this block. Q4: A 78-year-old woman with CKD stage 3b (eGFR 40) and stable heart failure is found to have a serum potassium of 5.9 mEq/L on a routine blood test. She is asymptomatic. Her current medications include lisinopril 40 mg daily, furosemide 40 mg daily, and an SGLT2 inhibitor. What is the most appropriate immediate step? A) Administer intravenous calcium gluconate B) Start sodium polystyrene sulfonate C) Review and discontinue non-essential medications and diet D) Add spironolactone 25 mg daily > Answer: C > Explanation: This patient is at risk of hyperkalemia from her CKD, RAAS inhibitor, and SGLT inhibitor. Immediate management focuses on identifying reversible causes and reviewing her medications (e.g., potassium supplements) and dietary intake. Discontinuing lisinopril or the SGLT
📚 Key References
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
- KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in CKD. ScienceDirect.
- Shlipak MG, et al. Synopsis of the 2024 KDIGO CKD Guideline. Ann Intern Med. 2025.
- KDIGO 2023 Controversies Conference on CKD-MBD. OUCI.
- Thyroid Dysfunction in CKD: A Cross-Sectional Study. PMC 2025.
This resource is intended for educational and examination preparation purposes. Always correlate with local institutional guidelines and consult a nephrologist for complex cases.
